Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Enrolling By Invitation NCT06723015

Tau PET Outcomes With Anti-amyloid Immunotherapies

Conditions: Cognitive Impairment, Mild, Dementia, Mild, Alzheimer Disease

Sex: All
Ages: 50 Years – 90 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 135
Sponsor: Mayo Clinic

Location: Mayo Clinic Rochester Minnesota

Summary

This is an imaging study of patients with mild Alzheimer's disease receiving amyloid-targeting therapy and under the care of neurologists at Mayo Clinic in Rochester, MN.

Eligibility Criteria

Inclusion Criteria * Age 50-90 years * Male or female * Mild cognitive impairment due to AD or mild AD * Amyloid positive via CSF or PET * Meets other eligibility criteria for anti-amyloid immunotherapy * Subject or delegate provides informed consent Exclusion Criteria * Subjects unable to lie down without moving for 10 minutes. * Women who are pregnant or cannot stop breast feeding for 24 hours. * Claustrophobic patients unable to tolerate the scans (no sedation can be offered).

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06723015). StuddyBuddy aggregates publicly available trial information.